{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:32:34Z","timestamp":1767832354291,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is caused by the constitutively active BCR-ABL tyrosine kinase. Although great progress has been made for improvement in clinical treatment during the past decades, it is common for patients to develop chemotherapy resistance. Therefore, further exploring novel therapeutic strategies are still crucial for improving disease outcome. MicroRNAs (miRNAs) represent a novel class of genes that function as negative regulators of gene expression. Recently, miRNAs have been implicated in several cancers. Previously, we identified 41 miRNAs that were dysregulated in resistant compared with adriamycin (ADR)-sensitive parental cells in CML. In the present study, we reported that miR-3142 are overexpressed in ADR-resistant K562\/ADR cells and CML\/multiple drug resistance patients, as compared with K562 cells and CML patients. Upregulation of miR-3142 in K562 cells accelerated colony formation ability and enhanced resisitance to ADR <jats:italic>in vitro<\/jats:italic>. Conversely, inhibition of miR-3142 expression in K562\/ADR cells decreased colony-formation ability and enhanced sensitivity to ADR <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Significantly, our results showed miR-3142-induced ADR resistance through targeting phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which led to downregulation of PTEN protein and activation of PI3 kinase (PI3K)\/Akt pathway. Inhibition of Akt using Akt inhibitor or introduction of PTEN largely abrogated miR-3142-induced resistance. These findings indicated that miR-3142 induces cell proliferation and ADR resistance primarily through targeting the PTEN\/PI3K\/Akt pathway and implicate the potential application of miR-3142 in cancer therapy.<\/jats:p>","DOI":"10.1038\/cddis.2017.223","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T16:54:22Z","timestamp":1495731262000},"page":"e2830-e2830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["RETRACTED ARTICLE: Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML"],"prefix":"10.1038","volume":"8","author":[{"given":"Lifen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujia","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3152-3253","authenticated-orcid":false,"given":"Li","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"BFcddis2017223_CR1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D . The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science 1986; 233: 212\u2013214.","journal-title":"Science"},{"key":"BFcddis2017223_CR2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H . Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 2014; 89: 547\u2013556.","journal-title":"Am J Hematol"},{"key":"BFcddis2017223_CR3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2009.016220","volume":"95","author":"AM Dickinson","year":"2010","unstructured":"Dickinson AM, Pearce KF, Norden J, O'Brien SG, Holler E, Bickeboller H et al. Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. Haematologica 2010; 95: 922\u2013927.","journal-title":"Haematologica"},{"key":"BFcddis2017223_CR4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFcddis2017223_CR5","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1182\/blood-2003-01-0083","volume":"102","author":"PT Ferrao","year":"2003","unstructured":"Ferrao PT, Frost MJ, Siah SP, Ashman LK . Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003; 102: 4499\u20134503.","journal-title":"Blood"},{"key":"BFcddis2017223_CR6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, NY) 2001; 293: 876\u2013880.","journal-title":"Science (New York, NY)"},{"key":"BFcddis2017223_CR7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Rosee P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321\u20131331.","journal-title":"Leukemia"},{"key":"BFcddis2017223_CR8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070\u20131079.","journal-title":"Blood"},{"key":"BFcddis2017223_CR9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.2007.06678.x","volume":"138","author":"A Fabarius","year":"2007","unstructured":"Fabarius A, Giehl M, Frank O, Spiess B, Zheng C, Muller MC et al. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. Br J Haematol 2007; 138: 369\u2013373.","journal-title":"Br J Haematol"},{"key":"BFcddis2017223_CR10","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","volume":"100","author":"ME O'Dwyer","year":"2002","unstructured":"O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002; 100: 1628\u20131633.","journal-title":"Blood"},{"key":"BFcddis2017223_CR11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005; 103: 1659\u20131669.","journal-title":"Cancer"},{"key":"BFcddis2017223_CR12","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","volume":"68","author":"FX Mahon","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008; 68: 9809\u20139816.","journal-title":"Cancer Res"},{"key":"BFcddis2017223_CR13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 2016; 127: 1269\u20131275.","journal-title":"Blood"},{"key":"BFcddis2017223_CR14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281\u2013297.","journal-title":"Cell"},{"key":"BFcddis2017223_CR15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857\u2013866.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017223_CR16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ng2003","volume":"39","author":"MS Kumar","year":"2007","unstructured":"Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T . Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673\u2013677.","journal-title":"Nat Genet"},{"key":"BFcddis2017223_CR17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.02.005","volume":"136","author":"A Ventura","year":"2009","unstructured":"Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136: 586\u2013591.","journal-title":"Cell"},{"key":"BFcddis2017223_CR18","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524\u201315529.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2017223_CR19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1126\/science.311.5757.36d","volume":"311","author":"G Ruvkun","year":"2006","unstructured":"Ruvkun G . Clarifications on miRNA and cancer. Science 2006; 311: 36\u201337.","journal-title":"Science"},{"key":"BFcddis2017223_CR20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0092-8674(00)80674-1","volume":"100","author":"A Di Cristofano","year":"2000","unstructured":"Di Cristofano A, Pandolfi PP . The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387\u2013390.","journal-title":"Cell"},{"key":"BFcddis2017223_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","volume":"95","author":"V Stambolic","year":"1998","unstructured":"Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29\u201339.","journal-title":"Cell"},{"key":"BFcddis2017223_CR22","doi-asserted-by":"crossref","first-page":"15406","DOI":"10.1073\/pnas.95.26.15406","volume":"95","author":"DM Li","year":"1998","unstructured":"Li DM, Sun H . PTEN\/MMAC1\/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998; 95: 15406\u201315411.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2017223_CR23","first-page":"2675","volume":"70","author":"ST Cha","year":"2010","unstructured":"Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010; 70: 2675\u20132685.","journal-title":"Cancer Res"},{"key":"BFcddis2017223_CR24","doi-asserted-by":"crossref","first-page":"ra62","DOI":"10.1126\/scisignal.2000356","volume":"2","author":"D Iliopoulos","year":"2009","unstructured":"Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2: ra62.","journal-title":"Sci Signal"},{"key":"BFcddis2017223_CR25","doi-asserted-by":"crossref","first-page":"60074","DOI":"10.18632\/oncotarget.11054","volume":"7","author":"L Zhao","year":"2016","unstructured":"Zhao L, Li Y, Song X, Zhou H, Li N, Miao Y et al. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Oncotarget 2016; 7: 60074\u201360086.","journal-title":"Oncotarget"},{"key":"BFcddis2017223_CR26","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1073\/pnas.211430998","volume":"98","author":"JR Testa","year":"2001","unstructured":"Testa JR, Bellacosa A . AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983\u201310985.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2017223_CR27","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","volume":"23","author":"DA Altomare","year":"2004","unstructured":"Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853\u20135857.","journal-title":"Oncogene"},{"key":"BFcddis2017223_CR28","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/ncomms2393","volume":"4","author":"J Bockhorn","year":"2013","unstructured":"Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013; 4: 1393.","journal-title":"Nat Commun"},{"key":"BFcddis2017223_CR29","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI66553","volume":"123","author":"Y Chen","year":"2013","unstructured":"Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M . CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest 2013; 123: 2395\u20132407.","journal-title":"J Clin Invest"},{"key":"BFcddis2017223_CR30","doi-asserted-by":"crossref","first-page":"9845","DOI":"10.1073\/pnas.1305472110","volume":"110","author":"A Vecchione","year":"2013","unstructured":"Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA 2013; 110: 9845\u20139850.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2017223_CR31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-07-2488","volume":"68","author":"H Yang","year":"2008","unstructured":"Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425\u2013433.","journal-title":"Cancer Res"},{"key":"BFcddis2017223_CR32","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.18632\/oncotarget.1614","volume":"5","author":"L Fang","year":"2014","unstructured":"Fang L, Li H, Wang L, Hu J, Jin T, Wang J et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014; 5: 2974\u20132987.","journal-title":"Oncotarget"},{"key":"BFcddis2017223_CR33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2010-03-277012","volume":"117","author":"DT Starczynowski","year":"2011","unstructured":"Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011; 117: 595\u2013607.","journal-title":"Blood"},{"key":"BFcddis2017223_CR34","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2014-06-581926","volume":"125","author":"LS Wang","year":"2015","unstructured":"Wang LS, Li L, Li L, Chu S, Shiang KD, Li M et al. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood 2015; 125: 1302\u20131313.","journal-title":"Blood"},{"key":"BFcddis2017223_CR35","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/leu.2012.65","volume":"26","author":"Y Yu","year":"2012","unstructured":"Yu Y, Yang L, Zhao M, Zhu S, Kang R, Vernon P et al. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. Leukemia 2012; 26: 1752\u20131760.","journal-title":"Leukemia"},{"key":"BFcddis2017223_CR36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","volume":"360","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P et al. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett 2015; 360: 245\u2013256.","journal-title":"Cancer Lett"},{"key":"BFcddis2017223_CR37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","volume":"356","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P et al. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett 2015; 356: 597\u2013605.","journal-title":"Cancer Lett"},{"key":"BFcddis2017223_CR38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.lungcan.2009.11.012","volume":"69","author":"G Jin","year":"2010","unstructured":"Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010; 69: 279\u2013283.","journal-title":"Lung Cancer"},{"key":"BFcddis2017223_CR39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/path.1611","volume":"204","author":"AR Panigrahi","year":"2004","unstructured":"Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO . The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004; 204: 93\u2013100.","journal-title":"J Pathol"},{"key":"BFcddis2017223_CR40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1750-3639.2004.tb00080.x","volume":"14","author":"M Mizoguchi","year":"2004","unstructured":"Mizoguchi M, Nutt CL, Mohapatra G, Louis DN . Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 2004; 14: 372\u2013377.","journal-title":"Brain Pathol"},{"key":"BFcddis2017223_CR41","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","volume":"65","author":"K Oda","year":"2005","unstructured":"Oda K, Stokoe D, Taketani Y, McCormick F . High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65: 10669\u201310673.","journal-title":"Cancer Res"},{"key":"BFcddis2017223_CR42","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ijc.22768","volume":"121","author":"M Ollikainen","year":"2007","unstructured":"Ollikainen M, Gylling A, Puputti M, Nupponen NN, Abdel-Rahman WM, Butzow R et al. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 2007; 121: 915\u2013920.","journal-title":"Int J Cancer"},{"key":"BFcddis2017223_CR43","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758\u2013764.","journal-title":"Nature"},{"key":"BFcddis2017223_CR44","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","volume":"13","author":"T Palomero","year":"2007","unstructured":"Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203\u20131210.","journal-title":"Nat Med"},{"key":"BFcddis2017223_CR45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3037","volume":"11","author":"MC Hollander","year":"2011","unstructured":"Hollander MC, Blumenthal GM, Dennis PA . PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289\u2013301.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017223_CR46","doi-asserted-by":"crossref","first-page":"10870","DOI":"10.18632\/oncotarget.7678","volume":"7","author":"J Xu","year":"2016","unstructured":"Xu J, Tang Y, Bei Y, Ding S, Che L, Yao J et al. miR-19b attenuates H2O2-induced apoptosis in rat H9C2 cardiomyocytes via targeting PTEN. Oncotarget 2016; 7: 10870\u201310878.","journal-title":"Oncotarget"},{"key":"BFcddis2017223_CR47","doi-asserted-by":"crossref","first-page":"27214","DOI":"10.18632\/oncotarget.4877","volume":"6","author":"S Dhar","year":"2015","unstructured":"Dhar S, Kumar A, Rimando AM, Zhang X, Levenson AS . Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget 2015; 6: 27214\u201327226.","journal-title":"Oncotarget"},{"key":"BFcddis2017223_CR48","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.canlet.2016.06.016","volume":"380","author":"J Gu","year":"2016","unstructured":"Gu J, Wang D, Zhang J, Zhu Y, Li Y, Chen H et al. GFRalpha2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Cancer Lett 2016; 380: 434\u2013441.","journal-title":"Cancer Lett"},{"key":"BFcddis2017223_CR49","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.18632\/oncotarget.2626","volume":"6","author":"ZJ Zou","year":"2015","unstructured":"Zou ZJ, Fan L, Wang L, Xu J, Zhang R, Tian T et al. miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation. Oncotarget 2015; 6: 1276\u20131285.","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1038\/s41419-020-2319-1","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"record-id":"22444"},{"DOI":"10.1038\/s41419-020-2319-1","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2017223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017223","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cddis.2017.223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:47:51Z","timestamp":1671731271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2017223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["BFcddis2017223"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2017.223","relation":{"retraction":[{"id-type":"doi","id":"10.1038\/s41419-020-2319-1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}